Src Reduces Neutrophil Extracellular Traps Generation and Resolves Acute Organ Damage.

Summary

This mechanistic study shows Src activation in neutrophils drives NETosis and correlates with prognosis in acute pancreatitis and sepsis. Genetic deletion or pharmacologic inhibition of Src reduced NET formation, ROS production via RAF/MEK/ERK signaling, and organ injury, positioning Src as a therapeutic target.

Key Findings

• Src is activated in neutrophils in NETosis models and correlates with prognosis in acute pancreatitis and sepsis patients.
• Src inhibition (genetic silencing or small-molecule inhibitors) suppresses NET formation and reduces acute inflammatory organ damage in vivo.
• Mechanistically, Src activates RAF1 (Ser621) and the RAF/MEK/ERK pathway, regulating intracellular ROS and NETosis; Src also engages PKC to drive this cascade.

Clinical Implications

Src inhibitors could be repurposed or developed to modulate NETosis in sepsis and acute pancreatitis; p-Src may serve as a biomarker. Clinical trials are needed to assess efficacy and safety.

Limitations

• Preclinical study without interventional clinical trials to confirm patient benefit.
• Disease contexts studied were acute pancreatitis and sepsis; generalizability to other inflammatory states requires testing.

Future Directions

Early-phase clinical trials of Src inhibition in sepsis/acute pancreatitis; development of pharmacodynamic biomarkers (p-Src, NET markers) and optimal timing based on immune state.